ALXO Stock News & Analysis | Latest Updates

ALX Oncology to Participate in Upcoming Investor Conferences in September

(NASDAQ:ALXO) SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in both the Cantor Global Healthcare Conference 2025 and H.C. Wainwright 27th Annual Global Investment Conference in New York.

August 29, 2025Conferences

ALXO News

ALX Oncology to Participate in Upcoming Investor Conferences in September

UBS Maintains Buy on ALX Oncology Holdings, Lowers Price Target to $1

ALX Oncology Unveils Clinical Development Plans For ALX2004, A ADC Targeting EGFR-Expressing Tumors, With Phase 1 Trials Set For Mid-2025 Following FDA IND Clearance And Initial Data Expected In 1H 2026, While Advancing CD47-Blocker Evorpacept In Breast A

HC Wainwright & Co. Maintains Buy on ALX Oncology Holdings, Lowers Price Target to $2

ALX Oncology Holdings Q1 Adj. EPS $(0.48) Misses $(0.46) Estimate

What's Next: ALX Oncology Holdings's Earnings Preview

ALX Oncology Announces Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma. Combination Generated Complete Responses In 83% Of Patients With Indolent Relapsed

ALX Oncology Announces ASPEN-03 And ASPEN-04 Phase 2 Trials Evaluating Evorpacept With A Checkpoint Inhibitor For The Treatment Of Head And Neck Cancers Did Not Meet Primary Endpoints

ALX Oncology Receives IND Clearance From FDA For ALX2004

Stifel Maintains Hold on ALX Oncology Holdings, Lowers Price Target to $1.5

HC Wainwright & Co. Reiterates Buy on ALX Oncology Holdings, Maintains $5 Price Target

ALX Oncology Holdings Q4 2024 Adj EPS $(0.44) Beats $(0.67) Estimate

This Zscaler Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Piper Sandler Maintains Overweight on ALX Oncology Holdings, Raises Price Target to $9

Jefferies Upgrades ALX Oncology Holdings to Buy, Raises Price Target to $3

Jefferies Downgrades ALX Oncology Holdings to Hold, Lowers Price Target to $2

ALX Oncology Announces Results From Phase 1b/2 Trial Of Evorpacept In Combination With Zanidatamab Will Be Presented At The San Antonio Breast Cancer Symposium 2024